Abstract
The pathophysiology of atopic dermatitis (AD) is linked to aberrant JAK/STAT pathway activation. The goal of the study was to characterize anti-inflammatory and anti-pruritic activity of ruxolitinib cream, a potent, selective JAK1/JAK2 inhibitor, during experimentally-induced dermatitis.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
